• +1-646-491-9876
    • +91-20-67278686

    Search

    Tyrosine Protein Kinase SYK-Pipeline Review H1 2017

    Tyrosine Protein Kinase SYK-Pipeline Review H1 2017

    • Report Code ID: RW0001834462
    • Category Pharmaceuticals
    • No. of Pages 104
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2017

    Summary

    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 3, 12 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Ophthalmology, Gastrointestinal, Hematological Disorders, Central Nervous System, Respiratory, Cardiovascular and Genito Urinary System And Sex Hormones which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia (CLL) , Allergic Conjunctivitis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Chronic Lymphocytic Leukemia (CLL) , Cutaneous Lupus Erythematosus, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) , Inflammation, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL) , Relapsed Chronic Lymphocytic Leukemia (CLL) , Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Allergies, Alzheimer's Disease, Anaphylactic Shock, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Urticaria Or Hives, Cutaneous T-Cell Lymphoma, Glomerulonephritis, Graft Versus Host Disease (GVHD) , Head And Neck Cancer Squamous Cell Carcinoma, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye) , Leukemias, Lupus Erythematosus, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease) , Multiple Sclerosis, Non-Small Cell Lung Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren) , Skin Inflammation, Solid Tumor and Systemic Lupus Erythematosus.

    Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
    - The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    AB Science SA
    Almirall SA
    Archer Pharmaceuticals Inc
    Asana BioSciences LLC
    Beijing Hanmi Pharmaceutical Co Ltd
    Celgene Corp
    Clevexel Pharma SAS
    F. Hoffmann-La Roche Ltd
    Fujifilm Corp
    Genosco Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Hutchison China MediTech Ltd
    Japan Tobacco Inc
    Levolta Pharmaceuticals Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    Portola Pharmaceuticals Inc
    Rigel Pharmaceuticals Inc
    Taiho Pharmaceutical Co Ltd
    TopiVert Ltd
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles
    AB-8779 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASN-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C-13 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CC-509 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cerdulatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CVXL-0074 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    entospletinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FF-10102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fostamatinib disodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-9876 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2646264 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HMPL-523 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JTE-852 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LAS-189386 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nilvadipine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRT-2761 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RO-9021 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKIO-703 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit SYK for Inflammation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-659 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAS-5567 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TOP-1210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TOP-1288 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TOP-1630 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TOP-1890 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products
    Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones
    Featured News & Press Releases
    May 30, 2017: Asana BioSciences Initiates Phase 2 Evaluation of ASN002, a Novel SYK/JAK Inhibitor, in NHL, CLL and MF
    May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
    May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
    Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States
    Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
    Mar 27, 2017: Asana BioSciences To Present New Data on ASN002 at AACR 2017
    Mar 16, 2017: Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis
    Jan 30, 2017: Fostamatinib Study Results Continue to Trend Positive
    Jan 10, 2017: Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China
    Dec 06, 2016: Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting
    Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
    Nov 28, 2016: TopiVert Receives IND Approval for TOP1630 in the Treatment of Dry Eye Syndrome
    Nov 14, 2016: Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting
    Nov 03, 2016: Takeda to Present Clinical Data on TAK-659 During 58th American Society of Hematology Annual Meeting
    Oct 20, 2016: Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1)
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AB Science SA, H1 2017
    Pipeline by Almirall SA, H1 2017
    Pipeline by Archer Pharmaceuticals Inc, H1 2017
    Pipeline by Asana BioSciences LLC, H1 2017
    Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017
    Pipeline by Celgene Corp, H1 2017
    Pipeline by Clevexel Pharma SAS, H1 2017
    Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Pipeline by Fujifilm Corp, H1 2017
    Pipeline by Genosco Inc, H1 2017
    Pipeline by Gilead Sciences Inc, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Hutchison China MediTech Ltd, H1 2017
    Pipeline by Japan Tobacco Inc, H1 2017
    Pipeline by Levolta Pharmaceuticals Inc, H1 2017
    Pipeline by Merck KGaA, H1 2017
    Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Pipeline by Portola Pharmaceuticals Inc, H1 2017
    Pipeline by Rigel Pharmaceuticals Inc, H1 2017
    Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
    Pipeline by TopiVert Ltd, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    AB Science SA
    Almirall SA
    Archer Pharmaceuticals Inc
    Asana BioSciences LLC
    Beijing Hanmi Pharmaceutical Co Ltd
    Celgene Corp
    Clevexel Pharma SAS
    F. Hoffmann-La Roche Ltd
    Fujifilm Corp
    Genosco Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Hutchison China MediTech Ltd
    Japan Tobacco Inc
    Levolta Pharmaceuticals Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    Portola Pharmaceuticals Inc
    Rigel Pharmaceuticals Inc
    Taiho Pharmaceutical Co Ltd
    TopiVert Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-syk-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-syk-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//tyrosine-protein-kinase-syk-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments